WallStSmart

Amphastar P (AMPH)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 1886% more annual revenue ($14.30B vs $719.89M). AMPH leads profitability with a 13.6% profit margin vs -24.6%. VTRS appears more attractively valued with a PEG of 0.14. AMPH earns a higher WallStSmart Score of 52/100 (C-).

AMPH

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 4.7Quality: 5.0

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMPHSignificantly Overvalued (-107.2%)

Margin of Safety

-107.2%

Fair Value

$13.80

Current Price

$19.57

$5.77 premium

UndervaluedFair: $13.80Overvalued

Intrinsic value data unavailable for VTRS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMPH2 strengths · Avg: 10.0/10
P/E RatioValuation
9.6x10/10

Attractively priced relative to earnings

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

AMPH4 concerns · Avg: 2.3/10
Market CapQuality
$899.28M3/10

Smaller company, higher risk/reward

PEG RatioValuation
2.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.8%2/10

Revenue declined 1.8%

EPS GrowthGrowth
-31.0%2/10

Earnings declined 31.0%

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : AMPH

The strongest argument for AMPH centers on P/E Ratio, Price/Book.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : AMPH

The primary concerns for AMPH are Market Cap, PEG Ratio, Revenue Growth.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

AMPH profiles as a declining stock while VTRS is a turnaround play — different risk/reward profiles.

AMPH carries more volatility with a beta of 0.92 — expect wider price swings.

VTRS is growing revenue faster at 5.0% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Bottom Line

AMPH scores higher overall (52/100 vs 50/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amphastar P

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?